Nottingham cancer detection company forms multi-million China distribution partnership

Nottingham early cancer detection company Oncimmune has?signed a framework distribution deal for a special licence with Genostics Company, a Hong Kong registered group that is part of China-based Gene Group.

Genostics will market Oncimmune’s EarlyCDT technology in China, where cancer would be the most important killer of both and women, along with 700,000 cases diagnosed annually.

The deal is expected to net 15.7m within the first six numerous post-market entry, and 5m 1 year after that.

As a part of the deal, Genostics invested 10m into Oncimmune by buying shares while in the company at a price of 1.56 per ordinary share, a 49% premium to the stock price of 105p.

This shall be allocated in two tranches, the primary 7m from a General Meeting anticipated to take place later in January 2018, along with the second (3m) by 30 March 2018. During the deal, an agent from Genostics can also be appointed towards the Oncimmune board – this could be announced once finalised.

Geoffrey Hamilton-Fairley, Leader of Oncimmune, said: “Oncimmune continues to deliver on our stated strategy whilst the IPO; an integral thing about this became a commercial agreement for China.

“Today, we’ve been happy to have signed a contract to the EarlyCDT? platform with Genostics with the People’s Republic of China, someone we have confidence offers the reach to produce on this huge market opportunity. We look forward to utilizing them and believe the funds in the equity subscription in this deal will unlock further opportunities across indications as well allowing us to produce technologies that may contribute to more lives being saved, together as cash is saved for healthcare systems.”

Dr. Cheung To, Chairman, Genostics Co. Limited, added?“Genostics is delighted to sign this agreement with Oncimmune and we are excited by way of the prospect of commercialising the EarlyCDT?platform in the People’s Republic of China. The test has proven it will detect cancer up to four years ahead of other methods which can significantly increase the outcomes for cancer patients through early detection within the disease and also raising the treatment pathway.

This deal means we can now provide early detection of cancer which augments our product portfolio inside our specialized portion of pathology and oncology. The EarlyCDT? platform is complementary for our current molecular diagnostic series which utilizes the latest PCR, sequencing and microarray technologies and, by combining forces with Oncimmune, we shall accelerate the technological and commercial continuing development of the EarlyCDT? platform, which can ultimately benefit more Chinese patients.”


Add a Comment

Your email address will not be published. Required fields are marked *